Quick Answer
FibroBiologics, Inc. reported Net Income of -$18.65 million for fiscal year 2025.
FibroBiologics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Net Income | -$18.65M -67.1% |
-$11.16M +32.3% |
-$16.48M -221.9% |
-$5.12M | — |
| Diluted EPS | -$0.42 -23.5% |
-$0.34 +50.0% |
-$0.68 -277.8% |
-$0.18 | — |
| Total Assets | $9.62M -41.5% |
$16.45M +39.1% |
$11.82M +145.0% |
$4.82M | — |
| Cash and Equivalents | $4.89M -65.0% |
$13.98M +52.6% |
$9.16M +304.4% |
$2.27M | — |
| Stockholders Equity | $6.16M +125.1% |
$2.73M +118.3% |
$1.25M +131.4% |
-$4.00M -209.8% |
-$1.29M |
| R&D Expense | $7.41M +64.5% |
$4.50M +90.2% |
$2.37M +106.5% |
$1.15M | — |
| Operating Income | -$16.65M -21.2% |
-$13.74M -54.5% |
-$8.89M -99.0% |
-$4.47M | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$5.78M | -1055.6% | -24.0% |
| Diluted EPS | September 30, 2025 | -$0.13 | -1200.0% | -8.3% |
| Total Assets | September 30, 2025 | $8.74M | -16.5% | -37.1% |
| Cash and Equivalents | September 30, 2025 | $4.87M | -37.8% | -45.0% |
| Stockholders Equity | September 30, 2025 | $125.0K | -95.4% | -85.5% |
| R&D Expense | September 30, 2025 | $2.79M | +129.9% | +36.6% |
| Operating Income | September 30, 2025 | -$5.04M | -50.3% | -12.2% |
- FibroBiologics, Inc. reported Net Income of -$18.65 million for fiscal year 2025.
- FibroBiologics, Inc. showed a decrease of -67.1% in Net Income compared to the prior fiscal year.
- FibroBiologics, Inc. reported Diluted EPS of $0.42 per share (loss) for fiscal year 2025.
- FibroBiologics, Inc. showed a decrease of -23.5% in Diluted EPS compared to the prior fiscal year.
- FibroBiologics, Inc. reported Total Assets of $9.62 million for fiscal year 2025.
- FibroBiologics, Inc. showed a decrease of -41.5% in Total Assets compared to the prior fiscal year.
- FibroBiologics, Inc. reported Cash and Equivalents of $4.89 million for fiscal year 2025.
- FibroBiologics, Inc. showed a decrease of -65.0% in Cash and Equivalents compared to the prior fiscal year.
- FibroBiologics, Inc. reported Stockholders Equity of $6.16 million for fiscal year 2025.
- FibroBiologics, Inc. showed an increase of +125.1% in Stockholders Equity compared to the prior fiscal year.
- FibroBiologics, Inc. reported R&D Expense of $7.41 million for fiscal year 2025.
- FibroBiologics, Inc. showed an increase of +64.5% in R&D Expense compared to the prior fiscal year.
- FibroBiologics, Inc. reported Operating Income of -$16.65 million for fiscal year 2025.
- FibroBiologics, Inc. showed a decrease of -21.2% in Operating Income compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: